NCT03492385View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

September 18, 2018

Study Completion Date

September 18, 2018

Conditions
Healthy
Interventions
DRUG

PB2452 Infusion

30 minute - 12 hour infusion

DRUG

Placebo - Sodium Chloride

30 minute - 12 hour infusion

DRUG

Ticagrelor Oral Tablet - Pre-Treatment

Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo

DRUG

Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment

Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo

Trial Locations (1)

78744

PPD, Austin

All Listed Sponsors
lead

SFJ Pharmaceuticals, Inc.

INDUSTRY

NCT03492385 - Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers | Biotech Hunter | Biotech Hunter